Clinical Trials Logo

Adenomatous Polyposis Coli clinical trials

View clinical trials related to Adenomatous Polyposis Coli.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04230499 Active, not recruiting - Clinical trials for Familial Adenomatous Polyposis

Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Start date: January 18, 2021
Phase: Phase 2
Study type: Interventional

Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp burden.

NCT ID: NCT03847636 Active, not recruiting - Clinical trials for Familial Adenomatous Polyposis

CryoBalloon Ablation for Treatment of Duodenal Adenomas

C2D2
Start date: May 13, 2019
Phase: N/A
Study type: Interventional

This multicenter prospective non-randomized interventional study (clinical trial) that will assess the safety and efficacy of cryoballoon ablation treatment using the C2 Cryoballoon device (Pentax Medical Corporation) as an alternative primary treatment modality for sporadic and familial nonampullary nonpolypoid (flat) duodenal adenomas.

NCT ID: NCT03806426 Active, not recruiting - Clinical trials for Familial Adenomatous Polyposis

Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis

Start date: December 5, 2018
Phase: Phase 3
Study type: Interventional

2 Year randomised, double-blind, placebo-controlled, parallel group study to determine the safety and efficacy of EPA-FFA gastro resistant capsules in FAP.

NCT ID: NCT01187901 Active, not recruiting - Clinical trials for Adenomatous Polyposis Coli

A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

FAPEST
Start date: April 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine in a randomized, placebo-controlled, phase II trial if the combination of sulindac and erlotinib causes a significant regression of duodenal and colorectal adenomas in familial adenomatous polyposis (FAP) and attenuated FAP patients.

NCT ID: NCT00134758 Active, not recruiting - Clinical trials for Adenomatous Polyposis Coli, Familial

Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients

Start date: October 2004
Phase: Phase 2/Phase 3
Study type: Interventional

Malignant transformation of adenomas of the duodenum is now the leading cause of death in familial adenomatous polyposis (FAP) patients who had a restorative proctocolectomy. Ursodeoxycholic acid (UDCA) modifies the biliary acid profile and could reduce the severity of duodenal adenomas and prevent such transformation.